Evidence map›Paper›PMID 34390213›Full record

Trial reportESC heart failure2021

A qualitative exploration of participant and investigator perspectives from the TRED-HF trial.

Vasiliki Papageorgiou, Kathryn Jones, Brian P Halliday, Richard Mindham, Jane Bruton, Rebecca Wassall, John G F Cleland, Sanjay K Prasad, Helen Ward

Abstract readClinical Trial
In one paragraph

Trial report in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vasiliki PapageorgiouPatient Experience Research Centre, School of Public Health, Imperial College London, London, UK.ORCID 0000-0002-2387-6780
Kathryn JonesPatient Experience Research Centre, School of Public Health, Imperial College London, London, UK.ORCID 0000-0003-0045-7206
Brian P HallidayNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-5876-1748
Richard MindhamRoyal Brompton and Harefield NHS Foundation Trust, London, UK.
Jane BrutonPatient Experience Research Centre, School of Public Health, Imperial College London, London, UK.ORCID 0000-0003-4477-4940
Rebecca WassallCardiovascular Research Centre and Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK.
John G F ClelandNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-1471-7016
Sanjay K PrasadNational Heart and Lung Institute, Imperial College London, London, UK.
Helen WardPatient Experience Research Centre, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-8238-5036

Funding

British Heart Foundation FS/15/29/31492British Heart Foundation FS/ICRF/21/26019Department of HealthWellcome TrustWellcome Trust 107469/Z/15/Z
6 · The paper itself

Abstract

aimsWe explored the experiences and motivations of participants and staff who took part in the TRED-HF trial (Therapy withdrawal in REcovered Dilated cardiomyopathy). METHODS AND

resultsWe conducted a qualitative study, using semi-structured interviews, with participants (n = 12) and the research team (n = 4) from the TRED-HF trial. Interviews were carried out in 2019 and were audio-recorded and transcribed. Data were managed using NVivo and analysed using framework analysis. A patient representative provided guidance on the interpretation of findings and presentation of themes to ensure these remained meaningful, and an accurate representation, to those living with dilated cardiomyopathy. Three key themes emerged from the data: (i) perception of health; (ii) experiences and relationships with healthcare services and researchers; and (iii) perception of risk. Study participants held differing perceptions of their health; some did not consider themselves to have a heart condition or disagreed with the medical term 'heart failure'. Relationships between participants, research staff, and clinical management teams influenced participants' experiences and decision making during the trial, including following clinical advice. There were differences in participants' perceptions of risk and their decisions to take heart failure medication after the trial was completed. Although the original TRED-HF trial did not provide the results many had hoped for, a strong motivator for taking part was the opportunity to withdraw medication in a safely monitored environment which had been previously considered by some participants before. Investigators acknowledged that the insights gained from the study can now be used to support evidence-based conversations with patients.

conclusionsFor people whose dilated cardiomyopathy is in remission, decisions to continue, reduce, or stop their medication are influenced by perceptions of personal health, perceive risk and the important of work, employment, recreation, relationships, and long-term plans. The unique relationship between patient and cardiologist provides opportunities to promote honest discussion about adherence to medication and personalized long-term management.

Indexed as

Cardiomyopathy, DilatedHeart FailureHumansQualitative ResearchCardiomyopathyDilatedFeasibility studiesMedication adherencePatient participationPhysician-patient relationsQualitative research

Identifiers

PMID34390213
PMCPMC8497205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.